Revance price target raised to $33 from $30 at Mizuho

Mizuho analyst Uy Ear raised the firm’s price target on Revance Therapeutics to $33 from $30 and keeps a Buy rating on the shares following the Q4 report. The analyst cites higher sales forecasts for Daxxify, partially offset by higher spending assumptions, for the target bump. The firm believes Revance’s strategy to prioritize prestige accounts that are likely to be early adopters should help shield it from potential macro headwinds in 2023.